Dr. Arif Kamal, Chief Patient Officer at the American Cancer Society,…
Dr. Arif Kamal, Chief Patient Officer at the American Cancer Society, breaks down “preventative chemotherapy” that Princess Kate is undergoing following…
Dr. Arif Kamal, Chief Patient Officer at the American Cancer Society, breaks down “preventative chemotherapy” that Princess Kate is undergoing following…
In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response…
In this issue of JAMA, Jabbour and colleagues1 report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with…
This randomized trial assesses the effect of ponatinib vs imatinib combined with low-intensity chemotherapy on disease remission in adults with newly diagnosed Philadelphia chromosome–positive acute…
Jason Efstathiou, MD, DPhil, Harvard Medical School, Boston, MA, gives an overview of treatment strategies for biochemical recurrent prostate cancer, including the role of radiotherapy…
Norman Wolmark, chairman of the NSABP Foundation Inc., and group chair and contact principal investigator of NRG Oncology, received the 2024 American Surgical Association Medallion…
The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.
Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on…
The requirement of large-scale expensive cancer screening trials spanning decades creates considerable barriers to the development, commercialisation, and implementation of novel screening tests. One way…
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk…